Likelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Gastric Cancer

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Gastric Cancer report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Lenvatinib Mesylate in Gastric Cancer Drug Details:

Lenvatinib mesylate (Lenvima / Kisplyx / Lenvixi) is a pyrrolopyrimidine derivative acts as anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). Lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentioated (papillary, follicular, Hurthel cell) thyroid carcinoma refractory to radioactive iodine and Kisplyx is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy and for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy and indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Lenvima is indicated for the treatment of unresectable thymic carcinoma and also indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced renal cell carcinoma.It is also under development for the treatment of advanced adrenocortical cancer, malignant pleural mesothelioma, Acral Lentiginous Melanoma, advanced/metastatic gastric cancer, metastatic esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, melanoma, oropharynx, hypopharynx, and/or larynx, locally advanced or metastatic gastrointestinal Stromal Tumor (GIST), neuroendocrine carcinoma, pediatric diffuse intrinsic pontine glioma, recurrent or metastaticsalivary gland cancers, anaplastic thyroid cancer, merkel cell carcinoma, pancreatic ductal adenocarcinoma, relapsed and refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma, ependymoma, high grade glioma,  triple-negative breast cancer, endometrial cancer, renal cell carcinoma (second line), hepatocellular carcinoma, bladder cancer, locally advanced or metastatic non-squamous non-small cell lung cancer, endometrial cancer, urothelial cancer, biliary tract cancer, advanced gastric cancer, adenoid cystic carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer (RET translocations), thymic carcinoma, endometrial cancer, fallopian tube cancer, peritoneal cancer, recurrent head and neck cancer squamous cell carcinoma, colorectal cancer, cutaneous squamous cell carcinoma and epithelial ovarian cancer, ampullary carcinoma, gallbladder carcinoma, prostate cancer, HER2 negative breast cancer, human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP) and mixed carcinoma. It is also under development for solid tumors in combination with pembrolizumab and for advanced or metastatic non clear cell renal cell carcinoma who have not received any chemotherapy for advanced disease. It was also under development for the treatment of recurrent or metastatic head and neck squamous cell carcinoma of oral cavity, metastatic urothelial carcinoma, lung adenocarcinoma, recurrent malignant glioma, liver fibrosis, endometrial cancer (monotherapy), melanoma and recurrent glioblastoma, breast cancer, metastatic melanoma, peripheral primitive neuroectodermal tumor (pPNET), leptomeningeal metastases from any solid tumor and non-small cell lung cancer (third-line, monotherapy).

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Quick View – Lenvatinib Mesylate LOA Data
Report Segments	· Drug type · Intervention type
Drug Name	· Lenvatinib Mesylate
Administration Pathway	· Oral
Therapeutic Areas	· Gastrointestinal| Infectious Disease| Oncology
Key Manufacturers	· Eisai Co Ltd
Drug Development Status	· Marketed

Reasons to Buy

• Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
• Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
• Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
• Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

Scope

• Drug Details: Drug name, Drug type, Intervention type
• Administration Pathway
• Therapeutic Areas
• Key Manufacturers
• Drug Development Status

This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.